Introduction
Oral lichenoid disease (OL�) includes di��erent chronic inflammatory processes with an immunological basis such as oral lichen planus (OLP) and oral lichenoid lesions (OLL) (1)� both entities with contro�ersial dia�-nosis and mali�nant potential (1) (2) (3) (4) . The clinical and histopatholo�ical links between OL� subt�pes are the presence o� lineal papular lesions with reticular pattern� usuall� associated with atrophic� erosi�e� ulcerati�e and plaque lesions; and the presence o� predominantl� l�m-phocytic chronic inflammatory infiltrate with a "band like" pattern and epithelial basal cell de�eneration (1�5). Clinical and histopatholo�ical di��erentiation between OLP and OLL is difficult, frequently even impossible to establish (2�6). Ne�ertheless� it seems that this di�-�erentiation is important� since some studies ha�e demonstrated that OLP and OLL ha�e di��erent mali�nant potential (1�7�8). OLP mali�nant trans�ormation rate has been reported to range between 0 to 5%, although it is considered not to exceed 1% (9) (10) (11) . �ue to the lack o� strict and uni�orm dia�nostic criteria �or OLP� se�eral studies ha�e included indistincti�el� cases o� OLP and OLL and e�en other lesions with a reco�nized mali�nant potential but neither lichenoid features nor inflammatory etiology such as leukoplakia and erithroplakia (2�3�12). Interestin� studies (7�8)� ha�e demonstrated that onl� lesions dia�nosed as OLL (based on strict clinical and histopatholo�ical dia�nostic criteria) showed mali�nant trans�ormation risk� su��estin� that the distinction o� these processes is crucial �or pro�nosis and treatment (2) . There�ore� finding molecular differences between both processes is important. To the best o� our knowled�e� no studies ha�e anal�zed the immunohistochemical expression o� biomarkers associated with oral carcino�enesis such as the epidermal �rowth �actor receptor (EGFR) in OLP and OLL� usin� the �an der Meij and �an der Waal histolo�ical dia�nostic criteria (2) . EGFR is a transmembrane �l�coprotein member o� the Erb �rowth �actor receptor �amil� (Erb1 o EGFR� Erb2� Erb3 � Erb4) which has been associated with oral carcino�enesis (13) (14) (15) (16) (17) . EGFR re�ulates se�eral mechanisms in�ol�ed in cell de�elopment and epithelial inte�rit� (15) . The EGFR has a t�rosine-kinase dependent action structured b� extracellular� transmembrane and intracellular zones. The bindin� o� the extracellular component to its respecti�e li�ands (EGF [epidermal �rowth �actor]� TGF-α [transforming growth factor], betaceluline, amphire�uline and here�uline)� acti�ates multiple intracellular stimulation and/or modulation pathwa�s (Ras/Ra�/ MAPK; P13K/AKT; PCL�amma; STATs) such as: cell proli�eration� di��erentiation� inhibition o� apoptosis� an�io�enesis� mi�ration and cellular in�asion (16) . Some studies ha�e demonstrated that EGFR is o�erex-pressed in oral squamous cell carcinoma (OSCC) (16)� and associated with positi�e l�mph nodes in patients with head and neck carcinomas (HNC) (18�19). Furthermore� other studies (13) (14) (15) (16) (17) ha�e demonstrated a pro�ressi�e increase o� EGFR expression� which was proportional to the se�erit� o� premali�nant lesions (13) . �espite the stron� association o� EGFR o�erexpression with oral carcino�enesis o� oral potentiall� mali�nant lesions (OPML)� �ew studies ha�e anal�zed its expression in OLP (20�21)� showin� contro�ersial results� and none in OLL. On one hand� Ebrahimi et al. (20) ha�e obser�ed low EGFR expression in OLP samples� in contrast� Kuma�ai et al. (21) obser�ed a hi�h expression in all their samples o� OLP. Encoura�ed b� the interestin� and reproducible results obtained b� �an der Meij and �an der Waal (7�8) and the stron� association o� EGFR expression and oral carcino�enesis� the aim o� our stud� is to anal�ze the di�-�erences in EGFR expression in OL� subt�pes such as OLP and OLL when dia�nostic histolo�ical criteria are emplo�ed; and also to correlate EGFR expression with the main clinical and histolo�ical �eatures.
Material and Methods
We ha�e studied 44 biopsies obtained �rom patients clinicall� and histopatholo�icall� dia�nosed with OL� in the Oral Medicine and Oral and Maxillo�acial Patholo�� �nit (�ental Clinic Ser�ice o� the �ni�ersit� o� Basque Countr�/EH�)� durin� the period o� Januar� 2006 to June 2008. Out of 44 patients, 30 (68.2%) were females and 14 (31.8%) males, with a mean age of 56.4 �ears (ran�e 31-82 �ears). Clinical and histopatholo�ical data were collected usin� a protocol based on previous studies (2, 3, 12) . Briefly, the clinical data like sex� a�e� t�pe and site o� the lesions were collected. Re�ardin� histopatholo�ical �ea-tures� presence or absence o� the main epithelial and inflammatory infiltrate characteristics were recorded and �raded in mild� moderate or se�ere in each case. Cases were clinically classified in: Group C1 with 26 (59.1%) cases with only papular reticular lesions, and Group C2 with 18 (40.9%) cases with papular reticular and other lesions such as atrophic� erosi�e� and ulcerati�e and/or plaque lesions. As inclusion criterion� none o� the patients should ha�e been recei�in� treatment �or OL� at the time o� the stud� or pre�ious to dia�nosis. The mean �ollow up time was 43.5 months (ran�e 20-78 months)� period in which no mali�nant trans�ormation was obser�ed in an� o� the cases.
-Histolo�� and Immunohistochemistr�
The cases were classified histopathologically following the dia�nostic criteria proposed b� �an der Meij and van der Waal (2) in an "histologically typical of OLP" (Group HT) with 23 (52.3%) cases, and "histologically compatible with OLP" (Group HC) with 21 (47.7%) cases. Briefly, HT cases had to show: (1) well-defined superficial "band like" predominantly lymphocytic chronic inflammatory infiltrate, (2) epithelial basal cell de�eneration� and (3) absence o� d�splasia; and HC cases did not show either one or none o� the characteristics described �or HT cases. Cases with epithelial d�splasia were excluded �rom the stud�. Samples o� oral mucosa without epithelial and/or inflammatory alterations and OSCC were emplo�ed as controls. All cases and controls underwent an hematox�lin and eosin standard histolo�ical procedure as well as con�entional immunohistochemical anal�sis. For immunohistochemical analysis, 4ųm paraffin sections were treated with a citrate bu��er solution at 100°C �or 2 minutes as anti�en retrie�al and incubated usin� the No�olink Pol�mer �etection Kit (No�o-castra®� New Castle �pon T�ne� �K) �ollowin� the manu�acturer´s instructions. All cases were incubated with the primar� prediluted monoclonal antibod� anti-EGFR protein (clon 31G7� Z�med Labs®� Camarillo CA� �SA.) �or 1 hour at room temperature. The antibod� emplo�ed has been tested pre�iousl� in other studies (18�22). For �isualization� sections were colored with the substrate/chromo�en 3�3= -diaminobenzidine (�AB) usin� the Pol�mer �etection Kit (No�ocastra ® � New Castle �pon T�ne� �K) showin� a �isible brown precipitate at the anti�en site. Based on pre�ious studies (23)� and considerin� the EGFR expression in controls� a semiquantitati�e anal�sis o� the expression percenta�e and the expression pattern o� epithelial cells was per�ormed� usin� the So�t Ima�e S�stem Cell A so�t-ware (Ol�mpus ® � Munster� German�). Immunohistochemical analysis was performed randomly in 5 fields b� 3 obser�ers (�C� JCC and JMA)� independentl� and without knowled�e o� clinical data� usin� a li�ht optic microscope Ol�mpus ® BX41 20x objecti�e and 10x ocular. A consensus a�reement was reached �or an� �i�en sample when discrepancies existed amon� obser�ers �or an� �i�en sample. The epithelial EGFR cell expression was assessed as follows: mild expression when <20% of epithelial cells were positi�e� moderate expression when ≥20% but <40% of epithelial cell were positive and severe expression when ≥40% of cells were positive. For statistical anal�sis� the �ariables were dichotomized in "low EGFR expression" when the expression was mild or moderate, and "overexpression of EGFR" when it was se�ere. The expression pattern was assessed in: membrane pattern (Mm)� c�toplasmatic pattern (Ct) and mixed membrane-c�toplasmatic pattern (Mm-Ct)� and the expression intensit� in mild� moderate and se�ere. For statistical anal�sis the cellular expression was dichotomized in mild and moderate-se�ere intensit�. The stud� was appro�ed b� the Ethics� In�esti�ation and Teachin� Committee (CEISH) o� the �ni�ersit� o� the Basque Countr�/EH�. The data underwent a descripti�e and comparati�e statistical anal�sis with X2 Pearson method and Fisher exact test� usin� the statistical so�tware SPSS (Version 15.0� SPSS Inc.� Chica�o� IL).
Results
As expected� �i�en the location o� proli�eratin� cells� the epithelial expression o� EGFR in controls o� nonaffected oral mucosa was confined to basal and parabasal cell la�ers with an Mm expression and scarce Ct expression pattern. In contrast� OSCC controls showed an intense EGFR expression in the peripher� and the center o� neoplastic nests� with a mixed Mm-Ct se�ere expression pattern (Fi�. 1). All cases showed EGFR expression in basal and parabasal epithelial cells. Thirty-nine cases (88.6%) showed EGFR expression in the spinous la�er and onl� in 5 (11.4%) cases reached the superficial layers. EGFR overexpression was recognized in 35 (79.5%) cases and low expression in 9 (20.5%) (Fig. 1) . We think that chronic inflammation mediators might be the main reason of this hi�h number o� cases with EGFR o�erexpression� rather than a hi�her mali�nant risk. All cases showed an Mm expression pattern, but in 31 (70.5%), we also obser�ed a Ct pattern� which was mild and moderatesevere in 13 (41.9%) and 18 (58.1%) cases respectively. This was an interesting finding because main EGFR expression pattern in non-a��ected oral mucosa controls was Mm rather than Ct� which in turn was intense in OSCC controls. We did not find significant differences in EGFR expression between the clinical and histolo�ical �roups (p>0.05) ( Table 1 )� su��estin� that the expression o� EGFR in OL� subt�pes does not seem to be completel� related with the se�erit� o� the clinical lesions� in other words� epithelial inte�rit� (ulcers and/or erosions) did not affect significantly EGFR expression. Out of the cases with EGFR overexpression, 17 (38.6%) cases showed a moderate-se�ere Ct expression pattern (Fi�. 1), 6 (40%) and 11 (84.6%) cases from HT and HC groups respectively showing a significant difference (p=0.016) ( Table  1) . This finding suggests, that when specific histological dia�nostic criteria (2) are applied there are di��erences in the cellular localization o� EGFR in OL� subt�pes� regardless of other histological features like inflammatory infiltrate intensity and/or epithelial thickness or inte�rit�. When we anal�zed the histopatholo�ical �eatures o� cases with EGFR o�erexpression� we onl� obser�ed significant differences regarding the keratinization type, since 19 (54.3%) of these cases showed parakeratosis compared with only 1 (11.1%) case without EGFR o�erexpression (p=0.027) ( Table 2 ). To this respect� we thought that is difficult to consider this association� since parakeratosis is �requentl� obser�ed in OLP and OLL samples. Howe�er� it mi�ht be reasonable to observe modifications in the epithelial lining features 
Group

Discussion
OLD includes different chronic inflammatory processes like OLP and OLL� characterized clinicall� b� the presence o� white lineal papular lesions in the oral mucosa (1). The mali�nant potential o� these processes is controversial and sometimes difficult to analyze due to the lack of defined and uniform diagnostic criteria emplo�ed in each stud� (7-10). Se�eral �ears a�o� �an der Meij and �an der Waal (2) proposed a clinical and histolo�ical dia�nostic criteria to di��erentiate t�pical cases o� OLP �rom those that were onl� compatible called OLL. These authors (2) demonstrated that when these criteria were applied� onl� cases dia�nosed as OLL showed an e�ident risk �or mali�nant trans�orma-tion (7�8). Althou�h a clear clinical and histopatholo�i-cal di��erentiation o� OLP and OLL is critical� an immunohistochemical anal�sis o� these processes would give valuable information about their molecular profiles and their possible mali�nant risk. The EGFR protein is a biomarker o� earl� carcino�en-esis (24�25)� o�erexpressed in se�eral oral premali�nant diseases (13�14�16). Moreo�er� EGFR has an s�ner�ic participation with other carcino�enesis biomarkers like c�cloox��enase-2 (COX-2)� inducible nitric oxide s�n-thase (iNOS) (26) (27) (28) . iNOS is associated with EGFR throu�h the stimulation o� STAT-3 (Si�nal Transducer and Acti�ator o� Transcription-3) and with COX-2 throu�h the s�nthesis o� prosta�landin (PGE2) (16) . The upre�ulation o� STAT-3 and COX-2 expression maintain directl� and/or indirectl� the EGFR intracellular pathwa�s� due to acti�ation o� other proteins in�ol�ed in this process� enhancin� oral carcino�enesis in OPML such as OLP and OLL (16�24). To this respect� pre�iousl� we ha�e demonstrated the o�erexpression o� COX-2 in these same samples (27) . These results ma� support the s�ner�� between EGFR and COX-2 and hi�hli�hts the possible pro�nostic implications o� this molecular interaction in OLP and OLL. Our stud� has demonstrated that EGFR is o�erexpressed in a �reat percenta�e o� OL� cases� showin� no di�-�erences between the clinical and histolo�ical �roups. These findings may suggest that the clinical type of lesions does not always reflect the molecular features o� OL� processes� in other words� the presence o� an erosive or ulcerative lesion "clinically more aggressive and strikin�"� not necessaril� implies an o�erexpression o� EGFR� and in the same wa�� the presence o� reticular white lesion "clinically less aggressive or striking", does not necessaril� impl� a low EGFR expression. It is worth mentioning that these findings were also obser�ed in a pre�ious stud� (27) when we anal�ze the COX-2 expression in these same cases. The histolo�ical HT and HC groups showed no significant differences in the EGFR o�erexpression� su��estin� that the presence or absence o� a particular histolo�ical �eature like an intense inflammatory infiltrate and/or extensive epithelial basal cell de�eneration or thickness it is not related with EGFR expression in OLP and OLL. These data indicate the existence o� other molecular mechanisms implicated in EGFR expression in OL� subt�pes. �ue to the lack o� clinical and histolo�ical separation in similar studies (20�21)� the comparison o� our results is difficult. However, our results contrast with those obtained b� Ebrahimi et al. (20) where� althou�h the� do not mention the t�pe o� clinical lesion o� their cases� the� obser�ed a low EGFR expression in OLP samples compared with controls. These authors (20) su��est that hi�h p53 expression in OLP or the presence o� mutated EGFR protein (EGFR �III) ma� explain the low EGFR expression in OLP. p53 protein is one o� se�eral control mechanisms o� EGFR expression (24�25)� thus its o�erexpression ma� explain EGFR low expression. Howe�er� se�eral studies (13�17�29) ha�e pointed out that EGFR mutations in OLP and other OPML is an uncommon e�ent. Moreo�er� se�eral studies (16�25�29) ha�e demonstrated that the expression o� EGFR �III is mainl� obser�ed in late oral carcino�enesis sta�es and alwa�s accompanied with the expression o� the wild t�pe EGFR protein. In this sense� the antibod� used in this stud� reco�nizes both wild and mutated EGFR protein, which makes it difficult to ensure the main type of EFGR protein detected in our stud�. Howe�er� based on pre�ious studies (13�17�29) and considerin� the low percenta�e o� cases with expression o� EGFR �III in OL� and other OPML� we assume that the main protein detected in our stud� is the wild t�pe EGFR protein. We ha�e demonstrated that EGFR o�erexpression was not associated with an� particular clinical or histolo�ical �eature� su��estin� that di��erent and/or more complex molecular mechanisms are in�ol�ed in this process. The main cause o� EFGR o�erexpression in OL� samples remains unknown. Howe�er� some authors (22) ha�e �ound that EGFR o�erexpression in other OPML with mali�-nant trans�ormation was associated with an increased EGFR �en cop� number� which can also be a possibilit� that need to be in�esti�ated in OL� subt�pes. Considerin� the low rate o� mali�nant trans�ormation of OLP (<1%) (9, 11) , it is obvious that the high percenta�e o� cases with EGFR o�erexpression herein obser�ed will not su��er a mali�nant trans�ormation� since se�e-ral �enetic alterations would be necessar� to make that possible. Ne�ertheless� the EGFR and COX-2 o�erex-pression pre�iousl� demonstrated (27) in these samples� ma� enhance the carcino�enic process in those �eneti-call� susceptible cases. There�ore� these molecular alterations can �i�e us �aluable in�ormation about intracellular pathwa�s altered in OL� subt�pes like OLP and OLL. So� with all the pre�ious back�round� we can propose two possible scenarios: the first that HC subtypes lesions with EGFR o�erexpression and increased Ct expression pattern ma� ha�e a di��erent biolo�ical beha�ior �rom those HT subt�pes lesions� which mi�ht be e457 possibl� associated with a hi�her mali�nant potential; the second scenario� ma� be that these di��erences in the EGFR expression pattern� could be the result o� di�-ferent molecular profiles involved directly or indirectly in EGFR immunoexpression in OLP and OLL� which is probabl� determined b� etiolo�ical �actors o� each process and ma� not be related with mali�nant potential. Howe�er� re�ardless the pro�nostic implication o� these immunohistochemical di��erences� we ha�e demonstrated that althou�h the clinical and histopatholo�i-cal �eatures are �er� similar in all OL� processes� there are molecular di��erences in each OL� subt�pe. We did not observe significant association between EGFR expression and an� particular histolo�ical �ea-ture� except �or keratinization t�pe� since more than 50% of the cases with EGFR overexpression showed parakeratosis. This finding has not been reported previousl� b� other authors (20�21). We do not know exactl� the meaning of this finding, or even if it has clinical rele�ance. Howe�er� considerin� that parakeratosis is a common finding in OLD samples it is very difficult to e�aluate this association. Ne�ertheless� what we do consider rele�ant is the lack o� association o� EGFR o�erex-pression with the presence and/or intensit� o� some particular features from the epithelial lining and inflammatory infiltrate. Inflammatory intensity and epithelial thickness are some o� the �eatures classicall� associated with the acti�it� o� OL� lesions. We belie�e that these findings may have relevance in those cases with mild histolo�ical acti�it� at dia�nosis and then de�elop mali�nant trans�ormation in a short period o� time. We can conclude that there is a hi�h EGFR o�erexpres-sion in OL� subt�pes� which increase their susceptibilit� to the EGFR stimulation e��ects like cell proli�era-tion� di��erentiation� apoptosis inhibition� an�io�enesis� mi�ration and cellular in�asion. Neither the clinical t�pe nor particular histolo�ical �eatures were associated with EGFR overexpression. Cases considered as "histolo�icall� compatible" (HC) or OLL show a �reater c�toplasmic EGFR expression� su��estin� biolo�ical di��erences with HT cases. The lon� term �ollow up o� these OL� patients will �i�e us more consistent in�or-mation about the significance of EGFR expression and mali�nant potential in these processes. Howe�er� �ur-ther studies are needed to ascertain the exact pro�nostic �alue o� EGFR expression in di��erent t�pes o� OPML like OLP and OLL.
